Targovax ASA: Third quarter 2022 results
Oslo, Norway, 3 November 2022 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its third quarter 2022 results. Members of Targovax’s executive management team will give an online presentation to investors, analysts and the press at 10:00 CET today (details below).THIRD QUARTER 2022 HIGHLIGHTS ONCOS-102 · The study protocol for the planned multi-cohort phase 2 in melanoma was approved by the US FDA · The phase 1b melanoma study results were selected for oral presentation at the